Current stock page

Financial Data

KURA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

KURAKura Oncology, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 4/10
$7.77+$0.34 (+4.58%)

Latest quote

  • Momentum
    40
  • Value
    70
  • Quality
    45
  • Risk resilience
    39
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$22.84M$20.87M$18.27M$17.34M$20.75M$15.29M$14.11M$53.88M
Gross Profit$22.47M$20.63M$17.65M$17.34M$17.54M$15.29M$14.11M$53.88M
Operating Income-$74.66M-$73.01M-$78.82M-$86.27M-$80M-$72.67M-$64.7M-$22.46M
Net Income-$70.22M-$68.33M-$73.33M-$81M-$74.12M-$66.12M-$57.43M-$19.22M
EPS-$0.78-$0.77-$0.83-$0.92-$0.85-$0.75-$0.66-$0.22
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$54.44M-$62.55M-$85.85M$117.27M-$80.63M-$28.78M-$71.93M$269.13M
Capital Expenditure-$445K-$656K-$128K-$2.32M-$2.57M-$1.46M-$292K-$372K
Free Cash Flow-$54.89M-$63.21M-$85.98M$114.95M-$83.19M-$30.24M-$72.22M$268.76M
Net Cash Provided By Operating Activities-$54.44M-$62.55M-$85.85M$117.27M-$80.63M-$28.78M-$71.93M$269.13M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$566.5M$587.79M$652.55M$738.36M$649.38M$682.43M$743.76M$760.16M
Total Debt$25.83M$24.46M$24.27M$20.46M$19.47M$19.47M$19.35M$16.59M
Cash And Cash Equivalents$57.94M$70.24M$39.08M$149.1M$95.29M$81.95M$51.27M$224.46M
Total Liabilities$548.54M$539.36M$544.67M$564.23M$406.84M$376.94M$379.36M$346.52M
Total Stockholders Equity$17.96M$48.43M$107.88M$174.14M$242.54M$305.49M$364.41M$413.64M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio38.6618.247.954.33.61.711.561.62
P/S ratio8.8———————
Debt To Equity1.440.50.220.120.080.060.050.04
Free Cash Flow Yield-12.84%-13.30%-9.85%-9.43%9.52%23.54%19.49%19.92%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio38.6618.247.954.33.61.711.561.62
P/S ratio8.8———————
Return On Equity-16.31%-6.13%-273.05%-160.03%-89.42%-64.54%-49.91%-42.06%
Debt To Equity1.440.50.220.120.080.060.050.04

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-2.35x
Pb38.86x
Revenue Growth Yoy10.07%
EPS Growth Yoy8.24%
Gross Margin98.45%
Operating Margin-394.32%
ROE-336.24%
ROIC-73.04%
Debt To Equity1.44
FCF Yield-12.48%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$7.77
Volume2.23M
RSI (14)37.1
MACD-0.79
MACD signal-0.67
MACD histogram-0.12
ADX (14)27.35
SMA (50)$10.17
SMA (200)$9.77
ATR (14)$0.67
Historical volatility (annualized)109.92%
Volume (20-day average)2.37M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score39/100
Beta1.33
Annual volatility63.01%
Max Drawdown-49.96%
Sharpe Ratio-0.25
VaR (95%, 1-day)-5.64%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

KURA Financial Data FAQ

What is Kura Oncology, Inc.'s revenue?

Kura Oncology, Inc.'s revenue is one of the core financial data points for KURA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Kura Oncology, Inc.'s revenue growing?

Revenue growth shows whether Kura Oncology, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is KURA's EPS?

KURA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Kura Oncology, Inc.'s net income?

Kura Oncology, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Kura Oncology, Inc. generate?

Free cash flow shows how much cash Kura Oncology, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Kura Oncology, Inc. have?

Cash and debt help frame KURA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.